ALK Actualización en terapias dirigidas en CPNM ALK+

4 / 48

Outline
ü ALK fusions as oncogenic driver
ü Diagnostic tools
ü Clinical characteristics NSCLC ALK+
ü Development and achievements with ALK TKIs
ü Sequencing treatments in ALK+
ü Resistance mechanisms